Researchers at Integra Therapeutics, in collaboration with the Pompeu Fabra University (UPF) Department of Medicine and Life ...

Uganda's flagship pharmaceutical and biotechnology giant, Dei BioPharma, has dismissed as false and malicious reports alleging a mass exodus of its senior scientists from the company's ...

The company has received a “limited number” of non-binding proposals, mostly from groups of financial investors, for a ...

Internet company The9 said Thursday its Singapore investee firm is expected to gain a Nasdaq listing and will have a roughly $1.5 billion pre-transaction equity value.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and ne ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: Agios ...

The government on Wednesday approved phase three of the biomedical research career programme aimed at training over 2,000 ...

Second-quarter sales of Enbrel, an arthritis treatment that first earned approval in 1998, declined by 34% year over year to ...

IBB offers diversified exposure to the biotech sector, focusing on large-cap leaders while maintaining positions in smaller ...

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.

Biotechnology firm Galapagos' board has received non-binding offers from consortia, mainly comprised of financial investors, for its cell-therapy business, the company said on Wednesday.

The evidence is crystal clear: the largest barrier to Alzheimer’s treatment in Latino communities is the stigma associated with cognitive decline.